Stories
Solara Active Pharma Shares Jump 10% As Company Returns To Profit
- •Solara Active Pharma shares surged over 10% to cross the 715 rupee mark following strong second-quarter results.
- •The company reported a profit of 28 crore rupees compared to a loss of 10 crore rupees in the same quarter last year.
- •Total revenue increased significantly from 313 crore rupees to 424 crore rupees driven by core business growth.
- •EBITDA more than doubled from 35 crore rupees to 77 crore rupees, with margins improving from 11.2% to 18.4%.
- •Net debt decreased by 114.1 crore rupees over six months, improving the net debt-to-EBITDA ratio from 3.2x to 1.8x.
Key Questions Answered
Solara Active Pharma reported a profit of ₹28.5 crore for the July-September quarter, recovering from a loss of ₹10.1 crore in the same period last year. Total revenue rose by 33% to ₹417.8 crore, and earnings per share stood at ₹5.92.
The company's net debt decreased by ₹114.1 crore over six months, dropping from ₹614.1 crore at the end of March 2026 to ₹500 crore at the end of September. This reduction was supported by ₹100 crore from a rights issue and ₹14.1 crore generated from operations.
The ibuprofen business generated ₹90.5 crore in revenue, which is up 21% from last year, while its EBITDA loss narrowed to ₹20 lakh, operating near break-even. The strategic review of this segment is in its final stages, with updates expected within 12 weeks.
